Literature DB >> 26868366

Cellular and molecular aspects of pancreatic cancer.

A Gharibi1, Y Adamian1, J A Kelber2.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that affects nearly 50,000 patients each year. The overall 5-year survival rate for this malignancy remains the lowest of any cancer at around 7% due to limited diagnostic methods, disease aggressiveness and a lack of targeted therapeutic interventions. This review highlights the successes achieved over the past several decades as well as the significant cellular and molecular hurdles that remain in combatting this deadly disease at a translational level.
Copyright © 2016 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Cancer progression; GEMMs; Kinases; Metabolism and desmoplasia; Pancreatic cancer; Therapy resistance

Mesh：

Year:  2016        PMID： 26868366      PMCID： PMC5654315          DOI： 10.1016/j.acthis.2016.01.009

Source DB:  PubMed          Journal:  Acta Histochem        ISSN： 0065-1281            Impact factor:   2.479


  104 in total

1.  Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].

Authors:  Yingchun Wang; Jonathan A Kelber; Hop S Tran Cao; Greg T Cantin; Rui Lin; Wei Wang; Sharmeela Kaushal; Jeanne M Bristow; Thomas S Edgington; Robert M Hoffman; Michael Bouvet; John R Yates; Richard L Klemke
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

2.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Authors:  Clara Montagut; Alba Dalmases; Beatriz Bellosillo; Marta Crespo; Silvia Pairet; Mar Iglesias; Marta Salido; Manuel Gallen; Scot Marsters; Siao Ping Tsai; André Minoche; Somasekar Seshagiri; Seshagiri Somasekar; Sergi Serrano; Heinz Himmelbauer; Joaquim Bellmunt; Ana Rovira; Jeff Settleman; Francesc Bosch; Joan Albanell
Journal:  Nat Med       Date:  2012-01-22       Impact factor: 53.440

3.  Kras, Pten, NF-κB, and inflammation: dangerous liaisons.

Authors:  Paul J Chiao; Jianhua Ling
Journal:  Cancer Discov       Date:  2011-07       Impact factor: 39.397

4.  Circulating tumor cells: finding the needle in the haystack.

Authors:  Xiaoning Zhe; Michael L Cher; R Daniel Bonfil
Journal:  Am J Cancer Res       Date:  2011-06-01       Impact factor: 6.166

Review 5.  The cancer cell secretome: a good source for discovering biomarkers?

Authors:  Maria P Pavlou; Eleftherios P Diamandis
Journal:  J Proteomics       Date:  2010-04-12       Impact factor: 4.044

6.  Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.

Authors:  Xiao Zhao; Feng Li; Yiye Li; Hai Wang; He Ren; Jing Chen; Guangjun Nie; Jihui Hao
Journal:  Biomaterials       Date:  2015-01-15       Impact factor: 12.479

7.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

8.  Identification of pancreatic cancer stem cells.

Authors:  Chenwei Li; David G Heidt; Piero Dalerba; Charles F Burant; Lanjing Zhang; Volkan Adsay; Max Wicha; Michael F Clarke; Diane M Simeone
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

9.  LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest.

Authors:  Jennifer P Morton; Nigel B Jamieson; Saadia A Karim; Dimitris Athineos; Rachel A Ridgway; Colin Nixon; Colin J McKay; Ross Carter; Valerie G Brunton; Margaret C Frame; Alan Ashworth; Karin A Oien; T R Jeffry Evans; Owen J Sansom
Journal:  Gastroenterology       Date:  2010-05-06       Impact factor: 22.682

10.  Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.

Authors:  Tiansuo Zhao; He Ren; Li Jia; Jing Chen; Wen Xin; Fan Yan; Jing Li; Xiuchao Wang; Song Gao; Dong Qian; Chongbiao Huang; Jihui Hao
Journal:  Oncotarget       Date:  2015-02-10
View more
  12 in total

Review 1.  Targeting reactive oxygen species in development and progression of pancreatic cancer.

Authors:  Nisha Durand; Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2016-11-23       Impact factor: 4.512

2.  CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.

Authors:  Xu-Hong Fu; Xiong Zhang; Hong Yang; Xiao-Wei Xu; Zong-Long Hu; Juan Yan; Xing-Ling Zheng; Rong-Rui Wei; Zhu-Qing Zhang; Shi-Rui Tang; Mei-Yu Geng; Xun Huang
Journal:  Acta Pharmacol Sin       Date:  2018-09-17       Impact factor: 6.150

Review 3.  Pancreatic Cancer, A Mis-interpreter of the Epigenetic Language.

Authors:  Eriko Iguchi; Stephanie L Safgren; David L Marks; Rachel L Olson; Martin E Fernandez-Zapico
Journal:  Yale J Biol Med       Date:  2016-12-23

4.  A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts.

Authors:  Malachia Hoover; Yvess Adamian; Mark Brown; Ali Maawy; Alexander Chang; Jacqueline Lee; Armen Gharibi; Matthew H Katz; Jason Fleming; Robert M Hoffman; Michael Bouvet; Robert Doebler; Jonathan A Kelber
Journal:  Oncotarget       Date:  2017-01-24

5.  Exosomes released from pancreatic cancer cells enhance angiogenic activities via dynamin-dependent endocytosis in endothelial cells in vitro.

Authors:  Mitsuru Chiba; Shiori Kubota; Konomi Sato; Satoru Monzen
Journal:  Sci Rep       Date:  2018-08-10       Impact factor: 4.379

6.  ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.

Authors:  Armen Gharibi; Sa La Kim; Justin Molnar; Daniel Brambilla; Yvess Adamian; Malachia Hoover; Julie Hong; Joy Lin; Laurelin Wolfenden; Jonathan A Kelber
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

Review 7.  The Use of Biomarkers in Early Diagnostics of Pancreatic Cancer.

Authors:  Lumir Kunovsky; Pavla Tesarikova; Zdenek Kala; Radek Kroupa; Petr Kysela; Jiri Dolina; Jan Trna
Journal:  Can J Gastroenterol Hepatol       Date:  2018-08-14

Review 8.  Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.

Authors:  Dimitrios Giannis; Dimitrios Moris; Andrew S Barbas
Journal:  Cancers (Basel)       Date:  2021-03-03       Impact factor: 6.639

9.  Attenuation of Pancreatic Cancer In Vitro and In Vivo via Modulation of Nrf2 and NF-κB Signaling Pathways by Natural Compounds.

Authors:  Marta Cykowiak; Robert Kleszcz; Małgorzata Kucińska; Jarosław Paluszczak; Hanna Szaefer; Adam Plewiński; Hanna Piotrowska-Kempisty; Marek Murias; Violetta Krajka-Kuźniak
Journal:  Cells       Date:  2021-12-16       Impact factor: 6.600

Review 10.  Role of Nrf2 in Pancreatic Cancer.

Authors:  Marta Cykowiak; Violetta Krajka-Kuźniak
Journal:  Antioxidants (Basel)       Date:  2021-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.